Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Subscribe To Our Newsletter & Stay Updated